Given current molecular classification tools such as epigenomic profiling, it might be worthwhile to prospectively document the SOX9–STAT3–PML axis and correlate its activity levels with current high-grade glioma methylation classes. The gene discussed is STAT3; the disease is central nervous system cancer.